Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 6, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1756-8722-6-36
Keywords
-
Categories
Funding
- Science and Technology Program of Quanzhou City, Fujian Province, China [2012Z5]
Ask authors/readers for more resources
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
